News
Investing.com -- Celcuity Inc. (NASDAQ: CELC) stock rose 5.2% after the clinical-stage biotechnology company announced it will hold a conference call on Monday, July 28, 2025, to reveal topline ...
Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.
New clinical trials are advancing treatments for cutaneous T-cell lymphoma, advanced solid tumors, pediatric sarcomas and ALK ...
Unpredictable FDA and funding woes delay crucial drug approvals, depriving thousands of patients access to vital treatments ...
The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.
Context Therapeutics Inc. (NASDAQ: CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context ...
12h
Zacks Investment Research on MSNRXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?Recursion Pharmaceuticals RXRX and Relay Therapeutics RLAY are pioneering the use of artificial intelligence (AI) in drug ...
Topline results from a second phase 3 trial of AD109-an investigational oral therapy combining aroxybutynin and ...
On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...
Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.
AB Science's new Phase 3 trial of masitinib for ALS has been cleared to launch in certain European countries, as well as in ...
A high dose of centanafadine was shown to be safe and effective at lowering ADHD symptoms for adolescents, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results